Baxter Recalls IV Nutrition and Blood-Collection Products After Particle Contamination Found

Baxter International has recalled two medical products used in hospitals, health care facilities, and home-care settings after potentially harmful stainless steel and fiberglass particles were discovered in certain lots. The U.S. Food and Drug Administration (FDA) published recall notices on Aug. 25, warning that the contaminated products could pose serious risks if particles enter a patient's bloodstream.

According to the FDA and Baxter, the affected products include one lot of 70 percent dextrose injection and one lot of anticoagulant sodium citrate solution. Both products are supplied in Baxter Viaflex containers and are used in medical procedures involving intravenous nutrition or blood collection.

The presence of foreign particles in products used around the bloodstream can be a significant safety concern. Baxter stated that stainless steel particles could potentially contribute to a life-threatening blood clot in the lungs and may result in permanent organ damage or death. Fiberglass particles may also cause irritation of veins, inflammation, allergic reactions, or blockages capable of damaging tissue or organs.

As of Aug. 25, Baxter said it had not received reports of adverse events associated with the recalled products.

Recalled Dextrose Injection

One of the affected products is 70 percent dextrose injection, which is used as a source of calories and fluids for patients who cannot obtain sufficient nutrition through normal eating or tube feeding.

Health care professionals may combine dextrose with other ingredients when preparing intravenous nutrition. The recalled product is a pharmacy bulk package and is not designed to be administered directly to patients on its own.

The affected dextrose product is lot Y495066, which carries an expiration date of July 31, 2027.

Baxter distributed this lot to health care providers and distributors in Alabama, Georgia, and Tennessee between July 25 and July 28.

Facilities that still have the recalled product have been instructed to stop using it and arrange for its return. Home-care providers that used the affected dextrose to prepare intravenous nutrition have also been advised to identify potentially affected patients and replace solutions prepared with the recalled lot.

The FDA's recall information provides additional details about the affected product and the reason for the action.

Blood-Collection Solution Also Recalled

The second recall involves anticoagulant sodium citrate solution. This product is used in certain blood donations and medical treatments to prevent blood from clotting while a machine separates and collects particular components of blood.

Unlike a conventional medication that is injected directly from its container, the sodium citrate solution comes into contact with blood as part of the collection process. Some of that blood is subsequently returned to the donor or patient. This means foreign particles present in the solution could potentially have a pathway into the bloodstream.

The affected sodium citrate solution is lot Y493475, with an expiration date of Dec. 31, 2027. Baxter said the lot was distributed to one U.S. customer between July 2 and July 11.

The customer was directed to stop using the affected units and return the remaining product. Baxter also said it was communicating directly with customers to provide instructions for identifying and returning recalled products.

The FDA has published the recall details and safety information for the affected sodium citrate solution.

What the Contamination Could Mean

Foreign particles in a medical solution can create different risks depending on their size, composition, and how they enter the body.

According to Baxter's recall information, stainless steel particles could potentially travel through the bloodstream and contribute to blood vessel blockage. In severe cases, such an obstruction could affect the lungs or other organs. Fiberglass particles may cause a different range of complications, including inflammation, irritation, allergic reactions, or tissue injury.

These risks do not mean that every person exposed to a recalled product will experience complications. However, the possibility of contamination is serious enough for manufacturers and regulators to remove affected lots from use.

Patients and consumers should not attempt to determine the safety of an affected medical product by examining it themselves. Health care providers and facilities should follow the manufacturer's recall instructions and consult the appropriate medical professionals when questions arise.

Part of a Recent Series of Baxter Recalls

The latest recalls come after another Baxter product was recalled in July.

That earlier action involved one lot of cefazolin and dextrose injection after cardboard was reportedly found inside an intravenous bag. Cefazolin is an antibiotic administered intravenously to treat bacterial infections and to help prevent infections associated with certain surgical procedures.

The FDA's July recall notice provides information about that earlier action. FDA recall notice for Baxter Cefazolin and Dextrose Injection

The series of recalls highlights the importance of quality control in the manufacture and packaging of products that are used directly in medical treatment. Even when a product is intended for use by trained professionals, contamination involving foreign material can create risks that are difficult to identify without specialized inspection.

What Health Care Facilities Should Do

Facilities that may have received the recalled products should check their inventories against the lot numbers listed in the FDA notices. Products matching the affected lots should no longer be used and should be handled according to Baxter's return instructions.

Providers working with home-care patients should also review whether any intravenous nutrition solutions were prepared using the recalled dextrose lot. Where applicable, affected patients should be contacted and replacement solutions arranged in accordance with medical guidance.

Patients who are concerned that they may have received a product involved in the recall should speak with their health care provider rather than stopping prescribed treatment on their own.

At present, Baxter has reported no adverse events associated with the two recalls as of Aug. 25. Nevertheless, the potential consequences described by the manufacturer and FDA explain why the affected lots are being removed from circulation.

The recalls also demonstrate why patients, caregivers, and medical facilities should pay attention to official safety notices. Product names alone may not be sufficient to determine whether something is affected. Lot numbers, expiration dates, and distribution information are often essential when identifying recalled medical products.

Source: U.S. Food and Drug Administration (FDA) recall notices and information released by Baxter International, published Aug. 25, 2026.

Disclaimer: This article is provided for general informational purposes and is not medical advice. Patients and health care providers should consult the FDA, Baxter, pharmacists, physicians, or other qualified health professionals for advice concerning a specific product, treatment, or potential exposure. Recall information can change, so readers should verify the latest details through official sources.